🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 06 Sep 2026 · EMA CTIS official data

Clinical Trials in Spain

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

219
Recent authorisations
94
Phase III trials
Spain
Selected country
Showing 219 trials
Phase III Nutritional and Metabolic Diseases Authorised 02/09/2026

A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).

Type 2 Diabetes mellitus
Tecnimede-Sociedade Tecnico-Medicinal S.A.
760 participants planned
Poland · Germany · Portugal · Italy · Spain
2025-524606-15-00 on CTIS ↗
Phase II Eye Diseases Authorised 01/09/2026

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompe' Farmaceutici S.p.A.
156 participants planned
Denmark · Italy · Germany · Hungary · Netherlands · Spain · Belgium · Portugal
2025-524748-37-00 on CTIS ↗
Phase III Neoplasms Authorised 01/09/2026

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).

Newly Diagnosed Multiple Myeloma
AstraZeneca AB
234 participants planned
Poland · Italy · Denmark · France · Sweden · Germany · Spain
2025-524014-29-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 31/08/2026

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)
Vaderis Therapeutics AG
125 participants planned
Hungary · Netherlands · Germany · France · Italy · Lithuania · Spain · Belgium
2025-524490-17-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 31/08/2026

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL)
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
261 participants planned
Czechia · Denmark · Croatia · Spain · Sweden · Finland · Portugal · Ireland · Netherlands · Norway
2025-524230-25-00 on CTIS ↗
Phase IV Nervous System Diseases Authorised 31/08/2026

Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population

Postoperative delirium
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
80 participants planned
Spain
2025-523070-16-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 31/08/2026

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

Type 2 diabetes (T2D)
Novo Nordisk A/S
175 participants planned
Spain · Hungary · Romania · Slovakia · Poland · Germany
2026-525465-42-00 on CTIS ↗
Phase I Neoplasms Authorised 28/08/2026

An Open-Label Study of IDE034 in Adult Participants with Locally Advanced/Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors -non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), endometrial cancer, high-grade serous ovarian cancer (HGSOC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), and castration-resistant prostate cancer (CRPC)
Ideaya Biosciences Inc.
15 participants planned
Spain
2026-526299-21-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/08/2026

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)
Institut De Recherches Internationales Servier IRIS
33 participants planned
Netherlands · Spain · Germany · France · Finland
2025-525128-88-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
Pfizer Inc.
33 participants planned
Spain · France · Italy · Ireland · Germany · Poland
2025-524825-42-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Gastrointestinal Cancers
Genmab A/S
67 participants planned
Italy · Belgium · France · Spain · Denmark · Netherlands · Germany
2025-524130-26-00 on CTIS ↗
Phase II Hormonal diseases Authorised 26/08/2026

Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly

Acromegaly
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
40 participants planned
Spain
2025-524253-14-00 on CTIS ↗
Phase I Not possible to specify Authorised 26/08/2026

Bioequivalence clinical trial of two formulations of empagliflozin/metformin

Healthy volunteers
Laboratorios Normon S.A.
30 participants planned
Spain
2026-527325-35-00 on CTIS ↗
Phase II Immune system processes Authorised 25/08/2026

A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)

Renal Transplantation
Nefro Avillion Clinical Development LLC
27 participants planned
Czechia · Spain · Portugal · Austria
2026-525646-29-00 on CTIS ↗
Phase I Neoplasms Authorised 25/08/2026

A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors

Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors (Testicular and Endometrial Cancer)
Context Therapeutics Inc.
36 participants planned
France · Spain
2025-523968-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 25/08/2026

A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis

Ocular Myasthenia Gravis
UCB Biopharma
46 participants planned
Hungary · France · Greece · Poland · Spain · Italy · Germany
2025-524757-14-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/08/2026

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

narcolepsy
Harmony Biosciences Management Inc.
92 participants planned
Belgium · Italy · Germany · France · Spain · Poland
2025-523821-17-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 25/08/2026

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Apollo Therapeutics Limited
138 participants planned
Hungary · Czechia · Germany · Bulgaria · Poland · Spain
2026-525673-39-00 on CTIS ↗
Phase II Neoplasms Authorised 25/08/2026

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Janssen Cilag International
123 participants planned
Sweden · Spain · Greece · Portugal · France · Hungary
2025-524793-42-00 on CTIS ↗
Phase II Neoplasms Authorised 25/08/2026

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

Solid tumor
Bristol-Myers Squibb Services Unlimited Company
116 participants planned
Greece · Hungary · Poland · Belgium · Spain · Netherlands · Germany · France · Portugal · Italy · Romania
2025-524905-34-00 on CTIS ↗
Phase I Neoplasms Authorised 24/08/2026

A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
TOLREMO therapeutics AG
25 participants planned
Italy · Spain
2025-523536-39-00 on CTIS ↗
Phase III Neoplasms Authorised 24/08/2026

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Pancreatic Adenocarcinoma
Revolution Medicines Inc.
281 participants planned
Sweden · Spain · France · Poland · Italy · Norway · Belgium · Germany · Czechia · Austria · Netherlands · Denmark
2025-524928-21-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 24/08/2026

Evaluation of the efficacy and safety of photodynamic therapy with BF-200 ALA (Ameluz®) in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma at any location.

Immunosuppressed patients with premalignant and malignant skin lesions, such as actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and basal cell carcinoma (BCC), due to chronic immunosuppression.
Dra. Elena González Guerra
120 participants planned
Spain
2026-526649-85-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)

​​HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer​
Laboratorios Farmaceuticos Rovi S.A.
97 participants planned
Romania · Spain · Bulgaria · Czechia · Latvia · Poland · Croatia · Slovakia
2025-524846-85-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 21/08/2026

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Polycythemia Vera
Deciphera Pharmaceuticals Inc.
106 participants planned
Austria · Czechia · Italy · Portugal · Germany · France · Hungary · Spain · Poland
2025-524669-25-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Gastrointestinal Stromal
Glaxosmithkline Research & Development Limited
302 participants planned
Italy · Portugal · Germany · Sweden · Poland · Romania · Finland · Greece · Norway · Spain · Netherlands · France · Hungary
2025-524934-24-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Intravenous AVT32-DRL_PB and Keytruda® as an Adjuvant Treatment in Participants with Stage IIB/C-III Melanoma Following Complete Resection

Stage IIB/C-III Melanoma
Alvotech Swiss AG
32 participants planned
Romania · Spain
2025-525093-11-00 on CTIS ↗
Phase III Eye Diseases Authorised 21/08/2026

A Randomized, Double-Masked, Placebo-Controlled Study Assessing the Efficacy and Safety Of Privosegtor (OCS-05) as add-on to IV Methylprednisolone in Participants with Optic Neuritis (PIONEER 1)

Optic Neuritis
Oculis Operations SARL
82 participants planned
Italy · Germany · France · Poland · Spain
2025-525075-91-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
K-Group Beta Inc.
197 participants planned
Germany · Spain · Italy · Belgium · Poland · France · Ireland
2025-524641-27-00 on CTIS ↗
Phase III Neoplasms Authorised 20/08/2026

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals Inc.
108 participants planned
Italy · Spain · Poland · France · Norway · Greece · Germany
2025-523252-31-00 on CTIS ↗
Phase III Eye Diseases Authorised 20/08/2026

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR

Stargardt Disease (STGD1)
Alkeus Pharmaceuticals Inc.
54 participants planned
Belgium · France · Spain · Italy
2026-525296-60-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/08/2026

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)

Solid Tumors
AstraZeneca AB
10 participants planned
Spain
2025-524171-22-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 20/08/2026

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis
Eidos Therapeutics Inc.
50 participants planned
Spain · Denmark
2026-526068-19-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 20/08/2026

J2S-MC-GZMS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D

Irritable Bowel Syndrome Diarrhea
Eli Lilly & Co.
186 participants planned
Germany · Poland · Spain · Belgium
2025-524973-17-00 on CTIS ↗
Phase III Mental Disorders Authorised 19/08/2026

JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)

Depressive Disorder, Major
Eli Lilly & Co.
228 participants planned
Poland · Greece · Spain · Germany
2025-522310-24-00 on CTIS ↗
Phase I Neoplasms Authorised 19/08/2026

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics Inc.
30 participants planned
Spain
2026-526777-42-00 on CTIS ↗
Phase I/II Neoplasms Authorised 18/08/2026

A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Solid Tumours
Terremoto Biosciences Inc.
228 participants planned
Spain · Ireland · Hungary · Romania · France · Portugal · Belgium · Poland
2025-525036-34-00 on CTIS ↗
Phase III Immune System Diseases Authorised 18/08/2026

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis

Ocular Myasthenia Gravis
UCB Biopharma
46 participants planned
Hungary · Greece · Italy · Spain · Germany · Poland · France
2025-524756-54-00 on CTIS ↗
Phase II Neoplasms Authorised 18/08/2026

A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab

Hepatocellular Carcinoma
Akeso Biopharma Co. Ltd.
37 participants planned
Poland · France · Spain · Italy
2025-524591-30-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 18/08/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
295 participants planned
Netherlands · Denmark · Germany · Spain
2025-525102-38-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/08/2026

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.

Dementia Alzheimer's type
Sanofi-Aventis Recherche & Developpement
266 participants planned
Spain · Germany
2025-524581-14-00 on CTIS ↗
Phase III Eye Diseases Authorised 17/08/2026

A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)
Amgen Inc.
255 participants planned
Slovakia · Latvia · Czechia · Poland · Spain · Hungary · Lithuania
2025-523500-72-00 on CTIS ↗
Phase I Neoplasms Authorised 17/08/2026

A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

Metastatic castration resistant prostate cancer
Novartis Pharma AG
26 participants planned
France · Italy · Spain · Germany
2025-524080-20-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 17/08/2026

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke

Stroke
Sinfatin S.L.
80 participants planned
Spain
2025-521693-33-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 17/08/2026

C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Pneumoccoccal Immunisation
Pfizer Inc.
1345 participants planned
Spain · Finland · Poland · Germany · Greece · Hungary · Italy
2025-523447-35-02 on CTIS ↗
Phase I/II Neoplasms Authorised 17/08/2026

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
30 participants planned
Italy · Germany · Spain · Finland · France
2025-524915-36-00 on CTIS ↗
Phase III Male Urogenital Diseases Authorised 17/08/2026

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC)
BioNTech SE
211 participants planned
Belgium · France · Spain · Italy · Poland · Germany · Hungary
2025-524445-27-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 14/08/2026

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

heart failure
Cardurion Pharmaceuticals Inc.
369 participants planned
Latvia · Slovakia · Lithuania · Hungary · Italy · Netherlands · Spain · Poland · Bulgaria · Czechia
2025-525033-31-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 14/08/2026

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)

Diagnosis of primary ITP according to the 2019 International Consensus Report that is previously untreated and requires treatment
Amgen Inc.
42 participants planned
Spain · Hungary · Germany
2026-525454-11-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 14/08/2026

Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
50 participants planned
Spain
2026-525550-11-00 on CTIS ↗
Phase IV Metabolism Authorised 14/08/2026

Phase IV Low Intervention Clinical Trial to Study Biomarkers of "inflammageing" and Senescence in Pre-diabetic Patients Treated with Metformin: A Study nested within the project “NLRP3 Inflammasome at the Crossroad of Vascular Inflammageing: A Novel Target for Senomorphic Drugs”.

Pre-diabetic Patients
Universidad Autonoma De Madrid
105 participants planned
Spain
2026-527080-15-00 on CTIS ↗
Phase II Neoplasms Authorised 13/08/2026

A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

HR-positive/HER2-negative advanced breast cancer
Medica Scientia Innovation Research S.L.
25 participants planned
Spain · Italy · Germany
2026-525328-10-00 on CTIS ↗
Phase III Neoplasms Authorised 13/08/2026

SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients

Breast Cancer
AstraZeneca AB
79 participants planned
Poland · Spain · France · Germany · Italy
2025-523444-12-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 13/08/2026

A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation

Chronic obstructive pulmonary disease (COPD)
Regeneron Pharmaceuticals Inc.
190 participants planned
Belgium · Italy · Spain
2025-524392-23-00 on CTIS ↗
Phase III Diagnosis Authorised 12/08/2026

International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies

Patients suffering from rhinitis / rhinoconjunctivitis, with well-controlled mild-to-moderate asthma or without asthma, due to the exposure to any of the allergen sources under investigation, for at least 2 years in case of seasonal allergenic sources or for at least 1 year in case of perennial allergenic sources.
ROXALL Medizin GmbH
140 participants planned
Germany · Spain
2025-524676-32-00 on CTIS ↗
Phase I Neoplasms Authorised 11/08/2026

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.
40 participants planned
Italy · Netherlands · France · Spain
2025-524805-34-00 on CTIS ↗
Phase I Neoplasms Authorised 11/08/2026

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Advanced solid tumors
Pfizer Inc.
52 participants planned
Netherlands · France · Spain
2025-522532-14-00 on CTIS ↗
Phase I/II Mental Disorders Authorised 11/08/2026

Bioequivalence clinical trial of two formulations of quetiapine.

Healthy participants
Laboratorios Alter S.A.
36 participants planned
Spain
2026-527162-72-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 11/08/2026

J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C

Irritable Bowel Syndrome - Constipation
Eli Lilly & Co.
70 participants planned
Belgium · Spain
2025-524974-41-00 on CTIS ↗
Phase I Neoplasms Authorised 10/08/2026

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corp.
60 participants planned
Italy · Belgium · Germany · France · Spain
2026-525217-31-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 10/08/2026

Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.

Stroke
Sinfatin S.L.
80 participants planned
Spain
2025-521689-86-00 on CTIS ↗
Phase I Neoplasms Authorised 10/08/2026

A Phase 1 Trial of GEN1119 in Participants with Solid Tumors

Solid Tumors
Genmab A/S
66 participants planned
Spain · France
2026-525610-62-00 on CTIS ↗
Phase III Immune system processes Authorised 10/08/2026

A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)

Primary IgAN
Novartis Pharma AG
5 participants planned
France · Spain
2025-522824-29-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 10/08/2026

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Overweight and obesity
Novo Nordisk A/S
315 participants planned
Netherlands · Belgium · Greece · Poland · Spain · Denmark · France · Bulgaria · Sweden
2025-524626-18-00 on CTIS ↗
Phase III Hormonal diseases Authorised 07/08/2026

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

Graves' Disease (GD)
Argenx
145 participants planned
Italy · Czechia · Spain · Denmark · Belgium · Romania · Latvia · France · Germany · Greece · Sweden · Poland · Lithuania · Bulgaria
2025-523333-26-00 on CTIS ↗
Phase IV Virus Diseases Authorised 07/08/2026

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial

Cytomegalovirus infection in solid-organ transplant recipients.
Centre Hospitalier Universitaire Vaudois
90 participants planned
France · Spain
2025-524845-28-00 on CTIS ↗
Phase IV Virus Diseases Authorised 07/08/2026

A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)

SARS-CoV-2 infection, Influenza infection
Gentofte Hospital, Moderna Inc.
410000 participants planned
Denmark · Spain
2026-526720-49-00 on CTIS ↗
Phase IV Virus Diseases Authorised 06/08/2026

CLINIC-CURE, a pilot exploratory clinical trial of analytical treatment interruption in people with HIV with a highly favorable profile

HIV
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
20 participants planned
Spain
2026-526395-23-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 06/08/2026

Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study

Colonization by methicillin-resistant S. aureus and gut microbiota in users of pre-exposure prophylaxis (PrEP) and people living with HIV (PLHIV) with STIs.
Instituto De Investigacion Marques De Valdecilla
392 participants planned
Spain
2025-525150-19-01 on CTIS ↗
Phase I/II Neoplasms Authorised 06/08/2026

Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer

Advanced solid tumours
Orion Corporation
104 participants planned
Spain
2026-525864-17-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/08/2026

A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART

HIV Infections
Viiv Healthcare UK Limited
81 participants planned
Spain
2024-518511-19-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 04/08/2026

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Idiopathic Pulmonary Fibrosis
AstraZeneca AB
139 participants planned
Poland · Hungary · Netherlands · Germany · Spain · Greece · Bulgaria · Italy · France · Denmark
2025-525016-41-00 on CTIS ↗
Phase I Not possible to specify Authorised 04/08/2026

Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it

Healthy Volunteers
Oryzon Genomics S.A.
30 participants planned
Spain
2026-525953-35-00 on CTIS ↗
Phase I Neoplasms Authorised 04/08/2026

A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer

Advanced Cancer
Sumitomo Pharma America Inc.
43 participants planned
Spain · Bulgaria · Poland · Romania
2025-524652-63-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

type 2 diabetes mellitus
AstraZeneca AB
183 participants planned
Germany · Bulgaria · Spain · Denmark
2025-523940-12-00 on CTIS ↗
Phase III Neoplasms Authorised 03/08/2026

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG
25 participants planned
France · Austria · Spain
2025-523724-47-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
179 participants planned
Denmark · Hungary · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Austria · Romania · Croatia · Poland · Estonia · Italy · Lithuania
2025-523884-39-00 on CTIS ↗
Phase I Neoplasms Authorised 03/08/2026

Feasibility clinical trial of the sequential combination of AloCelyvir and activated tumor-infiltrating lymphocytes (TILs) for the treatment of children and young adults with advanced neuroblastoma

High-risk relapsed/refractory (R/R) neuroblastoma (NB).
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
15 participants planned
Spain
2025-522006-21-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
194 participants planned
Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece
2026-525922-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
302 participants planned
France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal
2026-525923-26-00 on CTIS ↗
Phase I Neoplasms Authorised 31/07/2026

A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)

solid tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
39 participants planned
Spain
2026-525785-22-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/07/2026

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
50 participants planned
France · Denmark · Spain · Portugal
2025-525111-17-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/07/2026

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases
Eli Lilly & Co.
145 participants planned
Hungary · Czechia · Spain · Netherlands
2025-524858-34-00 on CTIS ↗
Phase I Neoplasms Authorised 29/07/2026

A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy

Advanced or metastatic solid tumours
Pliant Therapeutics Inc.
15 participants planned
Spain
2026-526116-36-00 on CTIS ↗
Phase I/II Skin and Connective Tissue Diseases Authorised 29/07/2026

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age

Acne
Sanofi Pasteur Inc.
189 participants planned
Spain · Germany · Poland
2025-521740-38-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 29/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.
AstraZeneca AB
2343 participants planned
Spain · Hungary · Germany · Poland · Italy · Bulgaria · Netherlands · Austria · Romania · Sweden · France · Greece · Slovakia · Czechia
2026-526304-79-00 on CTIS ↗
Phase II Neoplasms Authorised 28/07/2026

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)
Puma Biotechnology Inc.
30 participants planned
France · Poland · Spain
2026-525382-47-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 28/07/2026

STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)

ischemic heart disease
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
3500 participants planned
Spain · Norway
2026-525933-22-00 on CTIS ↗
Phase I Neoplasms Authorised 27/07/2026

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer

Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
44 participants planned
Portugal · Denmark · Spain · France
2025-522209-40-00 on CTIS ↗
Phase I Neoplasms Authorised 27/07/2026

A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms

Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Intermediate-1, Intermediate-2, or High-Risk Primary Myelofibrosis, High-risk Polycythemia Vera
Prelude Therapeutics Inc.
22 participants planned
Italy · France · Spain
2026-525484-40-00 on CTIS ↗
Phase II Neoplasms Authorised 27/07/2026

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK
26 participants planned
Spain · France · Germany · Norway
2025-522757-19-00 on CTIS ↗
Phase II Neoplasms Authorised 27/07/2026

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Janssen Cilag International
6 participants planned
Spain
2025-524816-13-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
1140 participants planned
Greece · Portugal · France · Slovakia · Bulgaria · Netherlands · Romania · Italy · Austria · Poland · Hungary · Spain · Czechia · Belgium
2025-522488-14-00 on CTIS ↗
Phase III Neoplasms Authorised 27/07/2026

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
125 participants planned
Italy · Greece · Spain · Belgium · France · Austria · Germany
2025-523819-11-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)

Participants Living with Obesity or Overweight with at least 1 comorbidity with or without Type 2 Diabetes Mellitus
AstraZeneca AB
1010 participants planned
Spain · Germany · Italy · Poland
2025-524688-19-00 on CTIS ↗
Phase III Neoplasms Authorised 27/07/2026

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH
233 participants planned
Poland · Italy · Germany · France · Spain
2025-523960-19-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/07/2026

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

Spinal Muscular Atrophy
Biogen Idec Research Limited
40 participants planned
Finland · Spain · Italy · Poland · Ireland · Germany · France
2025-524054-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 24/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.
AstraZeneca AB
1600 participants planned
Czechia · Italy · Hungary · Romania · Bulgaria · Sweden · Denmark · Poland · Spain · Norway · Finland · Greece · France · Germany
2025-523994-41-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 23/07/2026

IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
91 participants planned
Germany · Spain
2026-525185-21-00 on CTIS ↗
Phase III Hormonal diseases Authorised 23/07/2026

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

Classic Congenital Adrenal Hyperplasia (CAH)
Neurocrine Biosciences Inc.
71 participants planned
Czechia · Germany · Sweden · Portugal · Romania · Bulgaria · Italy · Austria · Spain
2025-524282-24-00 on CTIS ↗
Phase III Not possible to specify Authorised 23/07/2026

Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.

No medical condition
Chemo Research S.L.
1550 participants planned
Sweden · Czechia · Spain · Hungary · Poland · Finland · Romania
2026-525727-24-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 23/07/2026

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

Huntington’s Disease
Skyhawk Therapeutics Inc.
110 participants planned
Germany · Spain
2025-522263-14-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 22/07/2026

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

Advanced ALK-positive NSCLC
Triana Biomedicines Inc.
4 participants planned
France · Italy · Germany · Spain
2025-524418-27-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 22/07/2026

Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)

Respiratory syncytial virus infection–related respiratory disease
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
100000 participants planned
Spain
2026-526804-59-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/07/2026

Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)

Major cardiovascular events (MACE), spontaneous intracerebral hemorrhage
Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International
312 participants planned
Spain · Belgium
2025-523435-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 22/07/2026

Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)

advanced gastric cancer
Vall D Hebron Institute Of Oncology
38 participants planned
Spain
2026-525620-23-00 on CTIS ↗
Phase I Neoplasms Authorised 22/07/2026

Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma

surgically resectable recurrent high-grade glioma
Vall D Hebron Institute Of Oncology
10 participants planned
Spain
2025-524359-30-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 22/07/2026

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis

Refractory, difficult-to-treat Rheumatoid Arthritis
Bristol-Myers Squibb Services Unlimited Company
21 participants planned
Poland · Italy · Spain · Germany
2025-520666-22-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/07/2026

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Alnylam Pharmaceuticals Inc.
17 participants planned
Italy · Netherlands · Spain · Germany · Ireland
2025-523390-42-00 on CTIS ↗
Phase I Neoplasms Authorised 21/07/2026

Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

Advanced Malignant Tumors; High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Services Unlimited Company
20 participants planned
Spain · France · Italy
2025-523067-38-01 on CTIS ↗
Phase III Digestive System Diseases Authorised 21/07/2026

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis
Ipsen Bioscience Inc.
127 participants planned
Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway
2026-525242-29-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/07/2026

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

Neoplasms, Prostate
Glaxosmithkline Research & Development Limited
18 participants planned
Netherlands · France · Spain
2025-523874-17-00 on CTIS ↗
Phase II Immune System Diseases Authorised 21/07/2026

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

newly diagnosed amyloid light chain amyloidosis
Glaxosmithkline Research & Development Limited
17 participants planned
Italy · Greece · Spain
2025-522803-60-00 on CTIS ↗
Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

HIV-1
Gilead Sciences Inc.
183 participants planned
Poland · Italy · France · Spain · Germany · Netherlands
2025-524336-19-00 on CTIS ↗
Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

HIV-1
Gilead Sciences Inc.
183 participants planned
Netherlands · Poland · Germany · France · Spain · Italy
2025-524335-39-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 21/07/2026

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

Lichen Sclerosus
Leo Pharma A/S
205 participants planned
Italy · France · Spain · Poland · Germany
2025-524873-17-00 on CTIS ↗
Phase I Neoplasms Authorised 20/07/2026

Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3

Advanced Solid Tumor Types Known to Express B7-H3
Myricx Pharma Limited
40 participants planned
Spain
2025-524929-41-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 20/07/2026

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca AB
158 participants planned
Germany · Italy · Spain · France · Sweden
2025-523908-75-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease
Novartis Pharma AG
368 participants planned
Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary
2025-522227-99-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes Inc.
116 participants planned
Sweden · Finland · Belgium · Spain · Austria · Netherlands · France · Norway · Germany · Italy · Poland
2025-524711-36-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 17/07/2026

Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)

Hereditary Spastic Paraplegia Type 50 (SPG50)
Elpida Therapeutics SPC
12 participants planned
Spain
2025-524576-28-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 17/07/2026

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease

Pulmonary hypertension secondary to interstitial lung disease
Tectonic Operating Company Inc.
9 participants planned
Poland · Romania · Spain
2026-525810-80-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 17/07/2026

Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

Healthy participants
Laboratorios Alter S.A.
36 participants planned
Spain
2026-527164-32-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/07/2026

Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)

Central nervous system tumours
Hospital Universitario La Paz
30 participants planned
Spain
2026-525876-24-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 14/07/2026

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

Asthma
Glaxosmithkline Research & Development Limited
229 participants planned
Ireland · Spain · Germany · Czechia · Bulgaria · France · Belgium · Romania · Italy
2025-524463-20-00 on CTIS ↗
Phase III Neoplasms Authorised 14/07/2026

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic colorectal cancer
Merck Healthcare KGaA
323 participants planned
Belgium · Germany · France · Denmark · Poland · Spain · Netherlands · Italy · Austria
2025-524648-37-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc.
97 participants planned
France · Portugal · Spain · Slovakia · Italy · Germany · Poland
2025-524448-36-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 14/07/2026

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
337 participants planned
Poland · Belgium · Norway · Sweden · Austria · Germany · Denmark · Netherlands · France · Italy · Spain
2025-525088-34-00 on CTIS ↗
Phase II Immune System Diseases Authorised 13/07/2026

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

Antibody-mediated Kidney Disease
AstraZeneca AB
17 participants planned
France · Germany · Italy · Belgium · Poland · Spain
2025-524139-38-00 on CTIS ↗
Phase II Neoplasms Authorised 13/07/2026

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc.
20 participants planned
Netherlands · Germany · Spain
2026-525282-50-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 13/07/2026

Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.

Women with infertility and low ovarian reserve.
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
126 participants planned
Spain
2026-526292-37-01 on CTIS ↗
Phase I Neoplasms Authorised 13/07/2026

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma
Janssen Cilag International
175 participants planned
France · Spain · Germany · Denmark · Belgium
2026-525234-39-00 on CTIS ↗
Phase II Virus Diseases Authorised 13/07/2026

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

Long-term persistence of SARS-CoV-2
Goethe University Frankfurt
24 participants planned
Germany · Spain
2025-524442-10-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 10/07/2026

Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial

Myocardial fibrosis, Acute myocarditis
Spanish Society Of Cardiology
152 participants planned
Spain
2025-523092-33-00 on CTIS ↗
Phase II Neoplasms Authorised 09/07/2026

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
Elevar Therapeutics Inc.
14 participants planned
France · Spain
2025-523923-22-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/07/2026

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
Argenx
29 participants planned
Greece · Italy · Germany · Belgium · Netherlands · Spain · Poland
2025-522939-33-00 on CTIS ↗
Phase III Eye Diseases Authorised 08/07/2026

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

Allergic rhinitis/rhinoconjunctivitis due to house dust mites exposure
Probelte Pharma S.L.
174 participants planned
Spain
2026-526105-15-00 on CTIS ↗
Phase III Neoplasms Authorised 08/07/2026

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Osteosarcoma
Institut Gustave Roussy
508 participants planned
Sweden · Poland · Denmark · Finland · Netherlands · Italy · France · Spain
2023-505575-69-01 on CTIS ↗
Phase II Nervous System Diseases Authorised 08/07/2026

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

Narcolepsy
Eisai Limited
51 participants planned
Belgium · Italy · Spain · Germany
2025-523503-30-00 on CTIS ↗
Phase II Neoplasms Authorised 07/07/2026

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
Bristol-Myers Squibb Services Unlimited Company
123 participants planned
Belgium · Ireland · Germany · Norway · Italy · France · Spain
2025-524285-18-00 on CTIS ↗
Phase III Eye Diseases Authorised 07/07/2026

Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)

Cataract
Ntc S.r.l.
536 participants planned
Spain · Poland · Greece · Sweden · Italy
2026-525594-39-00 on CTIS ↗
Phase III Neoplasms Authorised 07/07/2026

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Pfizer Inc.
91 participants planned
France · Spain · Italy
2025-524717-86-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 07/07/2026

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
20 participants planned
Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal
2025-523369-32-00 on CTIS ↗
Phase III Neoplasms Authorised 07/07/2026

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

Multiple Myeloma
F. Hoffmann-La Roche AG
133 participants planned
France · Germany · Italy · Greece · Denmark · Czechia · Spain · Poland
2025-524028-23-00 on CTIS ↗
Phase III Neoplasms Authorised 06/07/2026

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
AbbVie Deutschland GmbH & Co. KG
194 participants planned
Portugal · Spain · France · Italy · Germany · Austria
2025-522563-15-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 06/07/2026

A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.

Tuberculosis
Glaxosmithkline Research & Development Limited
28 participants planned
Spain
2026-525790-39-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
613 participants planned
Denmark · Sweden · Poland · Estonia · Portugal · Latvia · Spain · Hungary · Germany · Finland · Italy · Belgium · France
2024-518016-39-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
550 participants planned
Germany · Romania · Greece · Norway · Netherlands · Poland · Lithuania · Czechia · Slovakia · Spain
2024-518213-25-00 on CTIS ↗
Phase III Mental Disorders Authorised 01/07/2026

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

First Episode Psychosis (FEP)
University Of Oxford
156 participants planned
Netherlands · Greece · Germany · Italy · Austria · Spain
2025-521929-32-01 on CTIS ↗
Phase I/II Neoplasms Authorised 01/07/2026

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc.
35 participants planned
France · Spain
2025-523438-24-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

Relapsed or Refractory Multiple Myeloma
Janssen Cilag International
206 participants planned
Poland · Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
19 participants planned
Belgium · Netherlands · Spain · Germany · Italy
2025-523127-21-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
257 participants planned
Finland · Belgium · Hungary · France · Denmark · Austria · Germany · Italy · Spain · Czechia · Norway · Poland
2025-522167-15-00 on CTIS ↗
Phase I/II Neoplasms Authorised 30/06/2026

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

solid tumor
Krystal Biotech Inc.
40 participants planned
France · Spain
2025-522723-98-00 on CTIS ↗
Phase II Neoplasms Authorised 30/06/2026

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

metastatic pancreatic adecarcinoma
Theriva Biologics S.L.
6 participants planned
Spain
2026-525566-21-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
45 participants planned
Spain · Belgium · France · Italy · Germany
2025-521971-29-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc.
165 participants planned
Greece · France · Italy · Belgium · Denmark · Germany · Poland · Czechia · Portugal · Austria · Spain · Romania
2025-521769-29-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/06/2026

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

Dravet Syndrome
Ionis Pharmaceuticals Inc.
11 participants planned
Spain · France · Belgium · Portugal · Germany
2025-523835-20-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 30/06/2026

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited
111 participants planned
France · Spain · Denmark · Ireland · Germany
2025-524397-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/06/2026

A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers

Treatment of several inflammatory diseases, including inflammation-related fibrosis and autoinflammatory diseases
Allinky Biopharma S.L.
42 participants planned
Spain
2026-525830-49-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
57 participants planned
Germany · Romania · France · Bulgaria · Belgium · Spain · Poland · Greece · Italy · Czechia
2025-524855-30-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
54 participants planned
Spain · Belgium · France · Germany · Slovakia · Romania · Bulgaria · Italy · Poland · Greece
2025-523871-44-00 on CTIS ↗
Phase III Neoplasms Authorised 29/06/2026

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
243 participants planned
Greece · Portugal · Germany · Belgium · Spain
2025-521712-19-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

Small Cell Lung Cancer
Pfizer Inc.
15 participants planned
France · Italy · Spain
2025-524686-24-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 29/06/2026

ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)

Obstructive sleep apnea syndrome, Obesity
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
345 participants planned
Spain
2026-525500-10-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

Non-small Cell Lung Cancer
AstraZeneca AB
11 participants planned
Spain · Germany
2025-523599-21-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/06/2026

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

Solid Tumors
Revolution Medicines Inc.
252 participants planned
France · Poland · Ireland · Spain · Greece · Germany · Italy · Sweden · Belgium
2025-524623-50-00 on CTIS ↗
Phase II Immune System Diseases Authorised 29/06/2026

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc.
36 participants planned
Netherlands · Romania · Poland · France · Italy · Spain
2025-523288-39-00 on CTIS ↗
Phase II Disorders of Environmental Origin Authorised 26/06/2026

“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.

IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.
Probelte Pharma S.L.
30 participants planned
Spain
2026-525628-13-00 on CTIS ↗
Phase III Immune System Diseases Authorised 24/06/2026

A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS

Multiple Sclerosis
F. Hoffmann-La Roche AG
54 participants planned
Spain · France · Poland · Italy
2025-523726-40-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 23/06/2026

The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial

infertility
Santiago Dexeus Font Fundacio Privada
240 participants planned
Spain
2025-524761-25-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 23/06/2026

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement
41 participants planned
Poland · Spain · France · Netherlands · Germany
2025-523403-29-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 23/06/2026

USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.

Hypoxemic episodes in patients undergoing gastroscopy, colonoscopy, or oral endoscopic ultrasound under deep sedation with oxygen therapy administration.
Hospital Universitario Rio Hortega
326 participants planned
Spain
2026-525766-21-01 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Hereditary Angioedema
Adarx Pharmaceuticals Inc.
45 participants planned
Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC
486 participants planned
Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc.
88 participants planned
Germany · France · Poland · Italy · Spain
2025-524488-18-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/06/2026

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc.
69 participants planned
Spain · Italy · France
2025-522587-33-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/06/2026

Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events

Coronary atherosclerosis
Daiichi Sankyo Europe GmbH
103 participants planned
Italy · Spain · Germany
2025-524625-41-00 on CTIS ↗
Phase I Neoplasms Authorised 22/06/2026

Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma

Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC
43 participants planned
Spain · Romania
2025-525158-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 19/06/2026

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

Systemic Sclerosis
Celgene Corp.
37 participants planned
Spain · Germany · France · Italy · Belgium
2025-524337-11-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 19/06/2026

Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i

Type 2 diabetes
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
60 participants planned
Spain
2025-523374-17-03 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 18/06/2026

Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product

Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc.
3 participants planned
Spain · France
2024-514190-21-00 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 18/06/2026

A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A.
44 participants planned
Spain
2026-525897-20-00 on CTIS ↗
Phase III Neoplasms Authorised 18/06/2026

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma
Fondazione GONO G.I.
212 participants planned
Spain · Germany · Italy
2025-524048-36-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/06/2026

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR
110 participants planned
Spain · Germany · Italy · Sweden · France · Luxembourg
2024-513496-40-00 on CTIS ↗
Phase I Neoplasms Authorised 17/06/2026

Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer

Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer
Rondo Therapeutics Inc.
34 participants planned
Spain
2025-524687-38-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company
318 participants planned
Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 17/06/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

Systemic sclerosis
Galderma S.A.
56 participants planned
Poland · Italy · Bulgaria · France · Greece · Spain · Croatia
2025-522294-11-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer

Solid Tumors
Theras Inc.
2999997 participants planned
Spain · Italy · France
2025-524690-16-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 16/06/2026

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Duchenne Muscular Dystrophy
Entrada Therapeutics Inc.
56 participants planned
Belgium · Italy · Netherlands · Spain
2025-525124-10-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB
516 participants planned
France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands
2024-519787-40-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/06/2026

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

Metastatic Prostate Cancer
AstraZeneca AB
45 participants planned
Belgium · Spain · Poland · Italy · Netherlands
2025-520626-37-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Stage I NSCLC
Merck Sharp & Dohme LLC
283 participants planned
Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain
2025-522643-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc.
228 participants planned
Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement
177 participants planned
France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 15/06/2026

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

C3 Glomerulopathy (C3G), Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum AB (publ)
69 participants planned
France · Italy · Spain · Germany
2025-524487-37-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation​
Merck Sharp & Dohme LLC
88 participants planned
Italy · Netherlands · France · Germany · Spain · Poland · Greece
2025-522038-29-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
Merck Sharp & Dohme LLC
109 participants planned
Greece · Netherlands · Sweden · France · Italy · Spain · Denmark
2025-522267-15-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
210 participants planned
Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria
2025-523674-16-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 11/06/2026

Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.

Refractory Lupus Nephritis
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
10 participants planned
Spain
2025-522449-23-00 on CTIS ↗
Phase III Otorhinolaryngologic Diseases Authorised 11/06/2026

Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS

chronic suppurative otitis media (CSOM)
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
88 participants planned
Spain
2026-525540-15-00 on CTIS ↗
Phase II Neoplasms Authorised 11/06/2026

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas
Gilead Sciences Inc.
45 participants planned
Spain · France
2025-524095-27-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 11/06/2026

Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease

Patients with celiac disease
Venter Pharma S.L.
42 participants planned
Spain
2026-525518-70-00 on CTIS ↗
Phase III Neoplasms Authorised 09/06/2026

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

Follicular Lymphoma
Merck Sharp & Dohme LLC
11 participants planned
France · Spain · Germany · Greece
2025-522777-10-00 on CTIS ↗
Phase I/II Neoplasms Authorised 09/06/2026

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc.
210 participants planned
Italy · France · Germany · Belgium · Spain · Netherlands
2025-523432-39-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 09/06/2026

Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis

Bronchiectasis
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
160 participants planned
Spain
2025-524454-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)

Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc.
496 participants planned
Norway · Czechia · Portugal · Austria · Poland · France · Spain
2025-522176-86-01 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

Small cell lung cancer extensive stage
Merck Sharp & Dohme LLC
79 participants planned
Germany · Poland · Greece · Italy · France · Spain
2025-521032-11-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/06/2026

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

Nonsegmental vitiligo
Novartis Pharma AG
80 participants planned
Germany · Spain · Netherlands · France · Italy
2025-522301-37-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 08/06/2026

PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)

ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus
500 participants planned
Spain
2026-525355-93-00 on CTIS ↗
Phase II Neoplasms Authorised 08/06/2026

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc.
94 participants planned
Spain · Italy · France
2025-523984-39-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 08/06/2026

Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?

Laparoscopic cholecystectomy
Fundacion Biomedica Galicia Sur
66 participants planned
Spain
2026-525783-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)

Advanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.
Medica Scientia Innovation Research S.L.
278 participants planned
Spain
2025-525144-18-00 on CTIS ↗
Phase III Neoplasms Authorised 08/06/2026

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC
234 participants planned
Belgium · Czechia · Germany · Denmark · Greece · Netherlands · Poland · Spain · Austria · Italy · France
2025-522818-23-00 on CTIS ↗
Phase II Therapeutics Authorised 08/06/2026

Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.

Parkinson's disease
Universidad Rey Juan Carlos
40 participants planned
Spain
2026-525701-12-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 08/06/2026

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer Inc.
318 participants planned
Spain · Germany · Poland · Czechia · Greece · Italy · Bulgaria · France · Hungary
2024-518587-12-00 on CTIS ↗
Phase I Neoplasms Authorised 08/06/2026

A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation

adenocarcinoma of the colon or rectum
Bayer Consumer Care AG
49 participants planned
Finland · Spain · Sweden · Italy · Denmark · Netherlands · Belgium
2025-523648-11-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026

KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.
Novartis Pharma AG
31 participants planned
Spain · Italy · France · Denmark · Belgium
2025-523537-26-00 on CTIS ↗
Phase II Virus Diseases Authorised 08/06/2026

Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.

HIV-1 infection
Instituto De Salud Carlos III
60 participants planned
Spain
2025-524363-20-01 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/spain (Accessed: 6 September 2026).

Embed this data ↗

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker. See who's running these trials in our Company Directory, or compare pay across these markets in the EU Salary Guide.